March 12th 2025
Adding antihistamines to atezolizumab led to a 46% OS rate and a 23% PFS rate in metastatic urothelial carcinoma.
UGN-102 Produces Comparable Responses Regardless of Surgery in NMIBC Subset
May 8th 2024Patients with newly diagnosed and recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer treated with UGN-102 displayed meaningful and similar responses and disease-free survival regardless of whether they underwent surgery.